Equities research analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO – Get Free Report) in a report released on Wednesday. The brokerage set a “hold” rating on the ...
Hosted on MSN1mon
CTSO: CytoSorbents Announces Rights Offering Which has the Potential to Substantially Increase Available LiquidityOn December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own ...
Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restricted Cash Currently on the Balance Sheet PRINCETON, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ...
Hosted on MSN1mon
CytoSorbents sees Q4 product revenue growth of 22%-25% Y/YCytoSorbents (NASDAQ:CTSO) has announced preliminary Q4 and full-year 2024 financial results.The company estimates Q4 product revenue between $9.0 million-$9.2 million vs. consensus of $9.45M ...
PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
CytoSorbents Corporation announced the commencement of a rights offering, distributing non-transferable Subscription Right Warrants to stockholders and certain warrantholders. The offering ...
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL ...
This was corrected on 01/05/2025 at 1:03 AM. The revised post deletes Q4 and FY24 product revenue consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback